Constanta V. Timcheva
Bulgaria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
Journal: British journal of cancer
Published: August 01, 2024
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Journal: Breast cancer research and treatment
Published: July 14, 2023
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Journal: Gynecologic oncology
Published: November 28, 2022
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Journal: Radiology and oncology
Published: February 25, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 08, 2022
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Journal: Clinical breast cancer
Published: April 12, 2021
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.
Journal: Clinical and experimental immunology
Published: April 24, 2020
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Journal: Bioscience trends
Published: February 06, 2020
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Journal: British journal of cancer
Published: January 26, 2018
Delays in diagnosis and treatment of breast cancer: a multinational analysis.
Journal: European journal of public health
Published: September 14, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026